Semaglutide Just Outperformed Every Approved Alcohol Treatment on the Market

The alcohol treatment field has been waiting for a new first-line medication for decades. What appears to have shown up is a weekly injection you’ve already heard of for a different reason.

A randomized clinical trial of once-weekly semaglutide — the active ingredient in Ozempic and Wegovy, a GLP-1 receptor agonist approved for type 2 diabetes and obesity — found it produced a 41.1 percent reduction in heavy drinking days among adults with alcohol use disorder and comorbid obesity. That reduction was 13.7 percentage points greater than placebo. The trial’s number needed to treat (NNT) was 4.3 — meaning for every 4.3 people treated with semaglutide, one additional person achieved meaningful improvement in heavy drinking behavior.

Every FDA-approved medication for AUD — naltrexone, acamprosate, disulfiram — has an NNT of 7 or higher. Semaglutide’s 4.3 is not a marginal improvement. It’s substantially better in direct comparison, in this trial, in this population.

The mechanism is not fully understood but is likely tied to GLP-1’s effects on the mesolimbic dopamine system — the same reward pathway that drives alcohol craving. GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens, and animal studies have consistently shown that GLP-1 agonism dampens alcohol-seeking behavior. The human trial results are aligning with what the neuroscience predicted.

Semaglutide also reduced total monthly alcohol consumption, number of drinks per drinking day, self-reported alcohol craving, and standard measures of harmful alcohol use. The effects were broad, not narrow.

Context that matters: this is one trial, in a population with both AUD and obesity — which is specifically the population in which GLP-1 agonists are currently indicated. The FDA hasn’t approved semaglutide for AUD. Using it off-label for alcohol treatment in someone without obesity or diabetes would raise questions the current evidence base can’t fully answer. The Veterans Affairs large observational study showing that people on GLP-1 agonists for diabetes were 14 percent less likely to develop any new SUD (alcohol, cannabis, cocaine, nicotine, or opioids) adds meaningful signal, but observational data carries confounding that RCTs don’t.

The practical question for addiction medicine right now: should clinicians who are already prescribing semaglutide to patients with obesity and AUD be having an explicit conversation about the potential effect on drinking? Almost certainly yes. That conversation is currently happening inconsistently — because semaglutide is still processed by most systems as a weight-loss drug, not a behavioral health intervention.

The people doing that integration right — treating the metabolic and addiction layers simultaneously — are ahead of where the field’s institutions are. The institutions will catch up. The question is how many people go untreated in the meantime.

Follow GLP-1 addiction research at /newsroom/substances/alcohol and /newsroom/category/science-medicine.